

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Service Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ORGANIZATION.

1. REPORT DATE (DD-MM-YYYY) 20/08/2018		2. REPORT TYPE Poster		3. DATES COVERED (From - To) 08/20-23/2018	
4. TITLE AND SUBTITLE Expression of Mobility Group Box 1 Protein in a Polytrauma Model Treated with ECLS at Ground Level and High Altitude				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Lt Col Sams, Valerie G				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 59th Clinical Investigations and Research Support 1100 Wilford Hall Loop, Bldg 4430 JBSA – Lackland, TX 78236-9908 210-292-7141				8. PERFORMING ORGANIZATION REPORT NUMBER 18009	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 59th Clinical Investigations and Research Support 1100 Wilford Hall Loop, Bldg 4430 JBSA – Lackland, TX 78236-9908 210-292-7141				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release. Distribution is unlimited.					
13. SUPPLEMENTARY NOTES MHSRS 2018, Kissimmee, FL, 20-23 August 2018					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			SSgt Erin Toth
			19b. TELEPHONE NUMBER (Include area code) 210-292-7141		

INSTRUCTIONS FOR COMPLETING SF 298

1. REPORT DATE. Full publication date, including day, month, if available. Must cite at least the year and be Year 2000 compliant, e.g. 30-06-1998; xx-06-1998; xx-xx-1998.

2. REPORT TYPE. State the type of report, such as final, technical, interim, memorandum, master's thesis, progress, quarterly, research, special, group study, etc.

3. DATES COVERED. Indicate the time during which the work was performed and the report was written, e.g., Jun 1997 - Jun 1998; 1-10 Jun 1996; May - Nov 1998; Nov 1998.

4. TITLE. Enter title and subtitle with volume number and part number, if applicable. On classified documents, enter the title classification in parentheses.

5a. CONTRACT NUMBER. Enter all contract numbers as they appear in the report, e.g. F33615-86-C-5169.

5b. GRANT NUMBER. Enter all grant numbers as they appear in the report, e.g. AFOSR-82-1234.

5c. PROGRAM ELEMENT NUMBER. Enter all program element numbers as they appear in the report, e.g. 61101A.

5d. PROJECT NUMBER. Enter all project numbers as they appear in the report, e.g. 1F665702D1257; ILIR.

5e. TASK NUMBER. Enter all task numbers as they appear in the report, e.g. 05; RF0330201; T4112.

5f. WORK UNIT NUMBER. Enter all work unit numbers as they appear in the report, e.g. 001; AFAPL30480105.

6. AUTHOR(S). Enter name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. The form of entry is the last name, first name, middle initial, and additional qualifiers separated by commas, e.g. Smith, Richard, J, Jr.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES). Self-explanatory.

8. PERFORMING ORGANIZATION REPORT NUMBER. Enter all unique alphanumeric report numbers assigned by the performing organization, e.g. BRL-1234; AFWL-TR-85-4017-Vol-21-PT-2.

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES). Enter the name and address of the organization(s) financially responsible for and monitoring the work.

10. SPONSOR/MONITOR'S ACRONYM(S). Enter, if available, e.g. BRL, ARDEC, NADC.

11. SPONSOR/MONITOR'S REPORT NUMBER(S). Enter report number as assigned by the sponsoring/ monitoring agency, if available, e.g. BRL-TR-829; -215.

12. DISTRIBUTION/AVAILABILITY STATEMENT. Use agency-mandated availability statements to indicate the public availability or distribution limitations of the report. If additional limitations/ restrictions or special markings are indicated, follow agency authorization procedures, e.g. RD/FRD, PROPIN, ITAR, etc. Include copyright information.

13. SUPPLEMENTARY NOTES. Enter information not included elsewhere such as: prepared in cooperation with; translation of; report supersedes; old edition number, etc.

14. ABSTRACT. A brief (approximately 200 words) factual summary of the most significant information.

15. SUBJECT TERMS. Key words or phrases identifying major concepts in the report.

16. SECURITY CLASSIFICATION. Enter security classification in accordance with security classification regulations, e.g. U, C, S, etc. If this form contains classified information, stamp classification level on the top and bottom of this page.

17. LIMITATION OF ABSTRACT. This block must be completed to assign a distribution limitation to the abstract. Enter UU (Unclassified Unlimited) or SAR (Same as Report). An entry in this block is necessary if the abstract is to be limited.

- ❖ Acute respiratory distress syndrome (ARDS) is the most severe form of acute lung injury, characterized by acute onset of hypoxemia, bilateral radiographic pulmonary infiltrates without cardiogenic pulmonary edema, and may lead to sepsis and multi-organ failure.
- ❖ Injuries incurred in austere environments, particularly in the combat setting, require immediate evacuation with en-route critical care support.
- ❖ Extracorporeal membrane oxygenation (ECMO) may be used to support ARDS patients during transport, including during aeromedical evacuation.
- ❖ High mobility group protein box 1 (HMGB1) is an important indicator of damage-associated molecular pattern (DAMP) expression and disease progression in ARDS.
- ❖ HMGB1 has been identified as a mediator of ARDS and is expressed in blood following activation of damaged cells.
- ❖ Little is known regarding HMGB1 expression in a pulmonary contusion model of ARDS supported by ECLS at ground level..
- ❖ Altitude change effect on HMGB1 expression during air transportation is also unknown

Hypothesis

We hypothesized that HMGB1 expression in systemic blood increases following chest contusion and that HMGB1 expression is affected by changes in altitude to a greater extent in injured animals supported by ECLS versus healthy animals on ECLS undergoing the same altitude exposure.




Figure 1. Mechanism of HMGB1 release
Courtesy of Prof. Ikuro Maruyama, Kagoshima University.

- ❖ Female Yorkshire pigs (54.17 ± 1.27 kg) (n=15) were anesthetized and received arterial and venous catheters, followed by tracheostomy.
- ❖ Following baseline measurements, animals were cannulated and veno-venous ECMO was initiated (CardioHelp, Maquet GmbH, Gettinge Group, Rastatt, Germany), via an Avalon 23 Fr. catheter inserted into the right jugular vein.
- ❖ Blood flow was 1.2-3 /min and sweep gas flow ranged at 4-8L/min. Continuous heparinization was started at cannulation and titrated to 30-50% higher than baseline ACT levels.
- ❖ Animals were then transported via a standard NATO litter fitted with a next-generation medical equipment rail kit (MERK, Smeed Technologies, Cummings, GA) to an adjacent building housing hypobaric chambers.
- ❖ The altitude simulation profile consisted of the multiple levels of simulated atmospheric exposure, and is depicted in Figure 2.
- ❖ Altitude exposure occurred in healthy state on Day 1, and injured state on Day 2.
- ❖ Injury consisted of bilateral pulmonary contusions using a modified captive-bolt stunner (Model ML, Karl Schermer, Packers Engineering, Omaha, NE) and chest tube placement.
- ❖ HMGB1 ELISA (IBL international, ST51011, NC, US) was utilized to analyze the level of HMGB1 in the blood at each time-point.
- ❖ Plasma free hemoglobin (pfHb) was measured in real time by spectrophotometer method.
- ❖ Plasma total protein concentration (PTPC) was measured by Pierce™. BCA protein assay kit (Thermo scientific, Rockford, IL, US)
- ❖ Post-mortem lung tissue samples were fixed by 10% normal buffered formalin and paraffin embedded, thickness 4 μm sliced tissues were stained by Hematoxylin & Eosin or primary antibody immunohistochemistry for HMGB1/TLR 4 (abcam, CA, US).




Figure 2 Altitude exposure profile




Figure 3. Post-mortem Image of Lungs after Bilateral Pulmonary Contusion Treated with ECMO




Figure 4. Post-Mortem Image of Lung Tissue after Bilateral Pulmonary Contusion Treated with ECMO




Figure 5. Histology image and diffused alveolar damage score in a bilateral pulmonary contusion model treated with ECMO




Figure 6. Dramatic change of of HMGB1 protein, pfHb and PTPC in a bilateral pulmonary contusion model treated with ECMO at ground level and high altitude during en-route care.

Conclusion

High altitude does not alter HMGB1, pfHb and PTPC to expression in uninjured animals. Bilateral pulmonary contusion causes a transient increase in HMGB1 and pfHb levels. The level of HMGB1 in the blood of non-survivors is significantly higher than survived group. Bedside assessment of HMGB1 and pfHb may be a useful monitoring capability during en-route care, and should be a part of precision medicine in the future.

Acknowledgements

This study was funded by the United States Air Force, and administered through the Air Force Medical Research and Development Command under Contract #FA8650-15-C-6692, PI: Dr. Andriy Batchinsky, MD. The study was conducted according to the principles set forth in the National Institute of Health Guidelines for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended.